Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005;102(17):5992-7. doi:10.1073/pnas.0502267102
Shimada J, Kwon HJ, Sawamura M, Schreiber SL. Synthesis and cellular characterization of the detransformation agent, (-)-depudecin. Chem Biol. 1995;2(8):517-25.
Tothova Z, Ebert BL. Doubling Down on Mutant RAS Can MEK or Break Leukemia. Cell. 2017;168(5):749-750. doi:10.1016/j.cell.2017.02.013
Xu H, Lee MS, Tsai PY, et al. Ablation of insulin receptor substrates 1 and 2 suppresses -driven lung tumorigenesis. Proc Natl Acad Sci U S A. 2018;115(16):4228-4233. doi:10.1073/pnas.1718414115
Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108-12. doi:10.1038/nature08460
Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004;64(24):8867-75. doi:10.1158/0008-5472.CAN-04-2938
Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-7. doi:10.1038/nature11003
Jalili A, Wagner C, Pashenkov M, et al. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst. 2012;104(21):1673-9. doi:10.1093/jnci/djs373
Kugel S, Sebastián C, Fitamant J, et al. SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell. 2016;165(6):1401-15. doi:10.1016/j.cell.2016.04.033
Hegi ME, Devereux TR, Dietrich WF, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994;54(23):6257-64.